

Highlights of This Issue 2271

SMALL MOLECULE THERAPEUTICS

- 2273**  **Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance**
Ping Chen, Nathan V. Lee, Wenyue Hu, Meirong Xu, Rose Ann Ferre, Hieu Lam, Simon Bergqvist, James Solowiej, Wade Diehl, You-Ai He, Xiu Yu, Asako Nagata, Todd VanArsdale, and Brion W. Murray
- 2282** **Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform**
Yilin Zhang, Shravan Kumar Sriraman, Hilary A. Kenny, Ed Luther, Vladimir Torchilin, and Ernst Lengyel
- 2294** **A Novel Small Molecule Activator of Nuclear Receptor SHP Inhibits HCC Cell Migration via Suppressing Ccl2**
Zhihong Yang, Angela N. Koehler, and Li Wang
- 2302** **Mechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC**
Xiaojun Liu, Yingjun Jiang, Billie Nowak, Sarah Hargis, and William Plunkett
- 2314** **Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines *In Vitro* and *In Vivo***
Barbara A. Helfrich, Jihye Kim, Dexiang Gao, Daniel C. Chan, Zhiyong Zhang, Aik-Choon Tan, and Paul A. Bunn Jr
- 2323** **BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia**
Li-Tzong Chen, Chiung-Tong Chen, Weir-Torn Jiaang, Tsai-Yun Chen, Joseph H. Butterfield, Neng-Yao Shih, John Tsu-An Hsu, Hui-You Lin, Sheng-Fung Lin, and Hui-Jen Tsai
- 2334** **Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases**
Maximilien Murone, Anne Vaslin Chessex, Antoine Attinger, Raghuvveer Ramachandra, Shankar J. Shetty, Girish Dagainakatte, Saumitra Sengupta, Sivapriya Marappan, Samiulla Dhodheri, Stefania Rigotti, Yogeshwar Bachhav, Silvano Brienza, Peter Traxler, Marc Lang, Michel Aguet, Vincent Zoete, Olivier Michielin, Courtney Nicholas, Faye M. Johnson, Murali Ramachandra, and Andres McAllister
- 2344**  **Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth**
Michele C. Smith, Mary M. Mader, James A. Cook, Philip Iversen, Rose Ajamie, Everett Perkins, Laura Bloem, Yvonne Y. Yip, David A. Barda, Philip P. Waid, Douglas J. Zeckner, Debra A. Young, Manuel Sanchez-Felix, Gregory P. Donoho, and Volker Wacheck
- 2357** **Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition *In Vitro***
Mir A. Hoda, Christine Pirker, Yawen Dong, Karin Schelch, Petra Heffeter, Kushtrim Kryeziu, Sushilla van Schoonhoven, Thomas Klikovits, Viktoria Laszlo, Anita Rozsas, Judit Ozsvar, Walter Klepetko, Balazs Döme, Michael Grusch, Balazs Hegedüs, and Walter Berger
- 2370** **Inhibition of Breast Cancer Metastasis by Presurgical Treatment with an Oral Matrix Metalloproteinase Inhibitor: A Preclinical Proof-of-Principle Study**
Arthur Winer, Maxwell Janosky, Beth Harrison, Judy Zhong, Dariush Moussai, Pinar Siyah, Nina Schatz-Siemers, Jennifer Zeng, Sylvia Adams, and Paolo Mignatti
- 2378** **Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic-Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104**
James W.T. Yates, Susan Ashton, Darren Cross, Martine J. Mellor, Steve J. Powell, and Peter Ballard
- 2388** **Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases**
Patrizia Sini, Ulrich Gürtler, Stephan K. Zahn, Christoph Baumann, Dorothea Rudolph, Rosa Baumgartinger, Eva Strauss, Christian Haslinger, Ulrike Tontsch-Grunt, Irene C. Waizenegger, Flavio Solca, Gerd Bader, Andreas Zoepfel, Matthias Treu, Ulrich Reiser, Pilar Garin-Chesa, Guido Boehmelt, Norbert Kraut, Jens Quant, and Günther R. Adolf
- 2399**  **Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells**
Gema Santamaría Nuñez, Carlos Mario Genes Robles, Christophe Giraudon, Juan Fernando Martínez-Leal, Emmanuel Compe, Frédéric Coin, Pablo Aviles, Carlos María Galmarini, and Jean-Marc Egly

Table of Contents

LARGE MOLECULE THERAPEUTICS

- 2413** *In Vivo* Antitumor Activity of a Recombinant IL7/IL15 Hybrid Cytokine in Mice
Yinhong Song, Yalan Liu, Rong Hu, Min Su, Debra Rood, and Laijun Lai
- 2422** *In Vitro* and *In Vivo* Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia
Urs B. Hagemann, Katrine Wickstroem, Ellen Wang, Adam O. Shea, Kristine Sponheim, Jenny Karlsson, Roger M. Bjerke, Olav B. Ryan, and Alan S. Cuthbertson

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

- 2432** FLIP: A Targetable Mediator of Resistance to Radiation in Non-Small Cell Lung Cancer
Kylie A. McLaughlin, Zsuzsanna Nemeth, Conor A. Bradley, Luke Humphreys, Izabela Stasik, Catherine Fenning, Joanna Majkut, Catherine Higgins, Nyree Crawford, Caitriona Holohan, Patrick G. Johnston, Timothy Harrison, Gerard G. Hanna, Karl T. Butterworth, Kevin M. Prise, and Daniel B. Longley
- 2442** Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma
Yong Qin, Jason Roszik, Chandrani Chattopadhyay, Yuuri Hashimoto, Chengwen Liu, Zachary A. Cooper, Jennifer A. Wargo, Patrick Hwu, Suhendan Ekmekcioglu, and Elizabeth A. Grimm
- 2455** The Tyrosine Kinase Inhibitor Imatinib Augments Extracellular Fluid Exchange and Reduces Average Collagen Fibril Diameter in Experimental Carcinoma
P. Olof Olsson, Renata Gustafsson, René in 't Zandt, Tomas Friman, Marco Maccarana, Emil Tykesson, Åke Oldberg, Kristofer Rubin, and Sebastian Kalamajski
- 2465** FTY720 (Fingolimod) Inhibits HIF1 and HIF2 Signaling, Promotes Vascular Remodeling, and Chemosensitizes in Renal Cell Carcinoma Animal Model
Cécile Gstalder, Isabelle Ader, and Olivier Cuvillier
- 2475** TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics
Jennifer J. Wheler, Filip Janku, Aung Naing, Yali Li, Bettzy Stephen, Ralph Zinner, Vivek Subbiah, Siqing Fu, Daniel Karp, Gerald S. Falchook, Apostolia M. Tsimberidou, Sarina Piha-Paul, Roosevelt Anderson, Danxia Ke, Vincent Miller, Roman Yelensky, J. Jack Lee, David Hong, and Razelle Kurzrock

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

- 2486** EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Tim N. Beck, Rachel Georgopoulos, Elena I. Shagisultanova, David Sarcu, Elizabeth A. Handorf, Cara Dubyk, Miriam N. Lango, John A. Ridge, Igor Astsaturov, Ilya G. Serebriiskii, Barbara A. Burtness, Raneeh Mehra, and Erica A. Golemis
- 2498** Genomic Landscape of Malignant Mesotheliomas
Shumei Kato, Brett N. Tomson, Timon P.H. Buys, Sheryl K. Elkin, Jennifer L. Carter, and Razelle Kurzrock
- 2508** Receptor Tyrosine Kinase Phosphorylation Pattern-Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment
Xiaoxiao Sun, Qiaoling Song, Li He, Lei Yan, Jingli Liu, Qing Zhang, and Qiang Yu

MODELS AND TECHNOLOGIES

- 2521** Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma
Qingling Huang, Valentina E. Schneeberger, Noreen Lueteteke, Chengliu Jin, Roha Afzal, Mikalai M. Budzevich, Rikesh J. Makanji, Gary V. Martinez, Tao Shen, Lichao Zhao, Kar-Ming Fung, Eric B. Haura, Domenico Coppola, and Jie Wu
- 2530** Biodistribution and Targeting of Anti-5T4 Antibody-Drug Conjugate Using Fluorescence Molecular Tomography
Anand Giddabasappa, Vijay R. Gupta, Rand Norberg, Parul Gupta, Mary E. Spilker, Joann Wentland, Brian Rago, Jeetendra Eswaraka, Mauricio Leal, and Puja Sapra
- 2541** Development and Application of a Novel Model System to Study "Active" and "Passive" Tumor Targeting
Amarnath Mukherjee, Binod Kumar, Koji Hatano, Luisa M. Russell, Bruce J. Trock, Peter C. Searson, Alan K. Meeker, Martin G. Pomper, and Shawn E. Lupold



 AC icon indicates Author Choice
For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

A liposomal platform encapsulating both the third generation P-gp inhibitor tariquidar and paclitaxel was developed to overcome paclitaxel resistance in ovarian cancer cells. Liposomal paclitaxel-treated cells had a diffuse pattern of β -tubulin expression (shown in green). Treatment with liposomal tariquidar/paclitaxel resulted in cell rounding and ring-like β -tubulin formations around the nucleus. The liposomal encapsulated tariquidar and paclitaxel synergistically inhibited cell viability, blocked proliferation, and caused G₂-M arrest in paclitaxel-resistant ovarian cancer cell lines. For details, see the article by Zhang, Sriraman, and colleagues on page 2282.



Molecular Cancer Therapeutics

15 (10)

Mol Cancer Ther 2016;15:2271-2550.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/15/10>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/15/10>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.